Cardiovascular Diseases, Cardiovascular Risk Factor, Health Behavior
Conditions
Brief summary
Prescribing lifestyle changes to patients who have cardiovascular disease (CVD) may be an extremely cost effective mechanism of improving health individually and for the NHS. Positive lifestyle changes such as improved diet, increased physical activity, quitting smoking and reducing alcohol consumption have been proven to reform the health status of individuals with CVD. S-PLAC 2 is a phase II study to determine the efficacy of a lifestyle prescription (L℞) in patients and healthcare practitioners in a secondary care setting (i.e. hospital clinics/wards).
Interventions
BEHAVIORALLifestyle Prescription (LRx)
Standard care during consultations with the addition of a physical lifestyle prescription
Sponsors
Public Health Wales
Cwm Taf University Health Board
University of South Wales
Study design
Allocation
NON_RANDOMIZED
Intervention model
SEQUENTIAL
Primary purpose
PREVENTION
Masking
NONE
Intervention model description
The study is an interventional controlled observational study based in the Secondary care setting. Control groups will be utilized through the mechanism of wait-listing the enrolment of recruitment centres into the study. Mixed methods will be used for both data collection and analysis. Historical clinical participant data (pre-intervention) will be collected by the PI. data will be collected immediately after the consultation and at 3 months post intervention.
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes
Inclusion criteria
* Age 18 and over * Able and willing to provide written informed consent * Understands written and spoken English * Either an in/out- patient of Cardiology
Exclusion criteria
* Participant is unwilling or unable to provide written informed consent * Participant is pregnant * Participant has a drug dependency
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| A prescription (LRx) being issued during a consultation | During month 7 of the study | Number of so-signed prescription (LRx) forms. Total number of forms to be co-signed = 60 |
| Patient view of the prescription (LRx) and consultation Questionnaire | During month 7 of the study | Completed study questionnaires. Total number of questionnaires to be completed = 120. Responses will be recorded to gain feedback from the patient participants regarding their thoughts and feelings of their consultation with and without the intervention of the prescription (LRx). Scale: 7 (minimum) to 41 (maximum). A lower value represents a better (more positive) outcome. |
| Healthcare practitioner (HCP) view of the prescription (LRx) and consultation questionnaire. | During month 7 of the study | Completed clinician questionnaire. Total number of questionnaires to be completed = 6. Responses will be recorded to gain feedback from the clinicians regarding their thoughts and feelings of their consultations with and without the intervention of the prescription (LRx). Sections: Section 1 scale: 9 to 54 (a lower score represents a better, more positive outcome) Section 2 scale: 8 to 48 (a lower score represents a better, more positive outcome) Section 3 scale: 6 to 36 (a lower score represents a better, more positive outcome) Total score available: 23 to 138 |
Countries
United Kingdom
Outcome results
None listed